Main Article Content

Dr Shafa Sarwar


Immune Thrombocytopenic Purpura, ITP, Pediatric Hematology, Case Presentation, Diagnosis, Treatment, Complications.


Background: The goal is to offer a comprehensive examination of the patient's clinical appearance, diagnostic evaluation, therapy, results, and any related complications.

Methods: A 6-year-old female child presented with a large whitening, purplish bruise on her left flank. The past medical history included neonatal jaundice, full immunization, and normal developmental milestones. Physical examination revealed purpura on the left flank, without hepatosplenomegaly or lymphadenopathy. The patient's vital signs were stable.

Management: The patient received initial treatment with IV Immunoglobulin (IVIG) and IV steroids. Subsequent treatment included oral steroids, leading to complications such as rubella and facial puffiness.

Conclusion: The conclusion highlighted the complexity and variability of ITP in children, emphasizing the necessity of interdisciplinary care, patient education, and continuous monitoring for achieving optimal outcomes.

Abstract 216 | PDF Downloads 226


1. Güngör, Tülin, et al. "Retrospective Evaluation of Children with Immune Thrombocytopenic Purpura and Factors Contributing to Chronicity." Pediatrics & Neonatology, vol. 60, no. 4, 2019, pp. 411-
2. Faki Osman ME. Childhood immune thrombocytopenia: Clinical presentation and management. Sudan J Paediatr. 2012;12(1):27-39. PMID: 27493327; PMCID: PMC4949815.
3. Shinno, Kazuma, et al. "Severe Immune Thrombocytopenia That Developed Immediately After COVID-19 in a School-aged Patient: A Case Report." Frontiers in Pediatrics, vol. 11, 2023,
4. Patel PA, Chandrakasan S, Mickells GE, Yildirim I, Kao CM, Bennett CM. Severe pediatric COVID-19 presenting with respiratory failure and severe thrombocytopenia. Pediatrics. (2020) 146:e20201437. 10.1542/peds.2020-1437
5. Behlivani E, Tragiannidis A, Hatzipantelis E, Panagopoulou P. Immune thrombocytopenia secondary to COVID-19 infection: report of two cases. Pediatr Blood Cancer. (2021) 68:e29175. 10.1002/pbc.29175
6. Dongre A, Jameel PZ, Deshmukh M, Bhandarkar S. Immune thrombocytopenic purpura secondary to SARS-CoV-2 infection in a child with acute lymphoblastic leukaemia: a case report and review of literature. BMJ Case Rep. (2021) 14:e245869. 10.1136/bcr- 2021-245869
7. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. (2002) 141:683–8. 10.1067/mpd.2002.128547
8. Alharbi MG, Alanazi N, Yousef A, Alanazi N, Alotaibi B, Aljurf M, et al. COVID-19 associated with immune thrombocytopenia: a systematic review and meta- analysis. Expert Rev Hematol. (2022) 15:157–66. 10.1080/17474086.2022.2029699
9. Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018 10:9-25.
10. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐ controlled trials. Am J Hematol. 2018 93:921-930.
11. Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood. 2019 doi:10.1182/blood-2018-11-852491.
12. Rosu, Vasile E., et al. "Predictor Factors for Chronicity in Immune Thrombocytopenic Purpura in Children." Children, vol. 10, no. 6, 2023, p. 911,